Filter by
Our projects (109)
RSSShowing results 80 to 100
Accelerating implementation of low-dose primaquine for malaria controlThe IMPRIMA project is working with national stakeholders and communities to ensure the successful introduction of new...
A platform for evaluating Lassa fever treatmentsThe INTEGRATE project is creating a clinical trial platform able to support efficacy studies on multiple Lassa fever therapeutics.
Rapid detection of Ebola virus infectionsThe EPoCA project is developing an innovative new point-of-care test for Ebola virus infections that will also give insights into infection severity...
Extending ivermectin use to young childrenThe IVM-KIDS project is developing a child-friendly formulation of ivermectin to ensure young children can benefit from this key drug for parasite...
Boosting the use of anti-parasite drugs during pregnancyThe TreatPreg project is assessing whether a mix of anti-parasite drugs can be given together during pregnancy to prevent anaemia and...
Training new African ‘bioentrepreneurs’The SAHRI Fellowship project provides promising researchers from sub-Saharan Africa with a structured three-year training programme that includes a 6...
Our overall objective is to integrate our consortium’s individual skills, capacity and innovations into advanced, low-cost and deployable digital dashboards and diagnostics to understand how...
Background: Monkeypox virus (MPV) is a member of the Poxviridae family that includes smallpox, cowpox and chickenpox viruses. Endemic to equatorial Africa following casual human to animal or...
Enhancing genomic surveillance in the Great Lakes regionThe GREAT-LIFE project is building a genomics-based infrastructure to track existing and new infectious disease threats and...
Building genomic surveillance capacity in EthiopiaThe EpiGen Ethiopia project is bringing together multiple partners to strengthen the country’s capacity to detect and track known and...
We recently described the novel clade Ib mpox virus from Kamituga, South Kivu, which fast spread in the region and severe symptoms are the reason for the emergency call for mpox research...
This proposal is submitted in response to the Global Health European and Developing Countries Clinical Trials Partnerhsip-3 (GH EDCTP3) Joint Undertaking (JU) call: “HORIZON-JU-EDCTP3-2025...
Despite available efficacy data on two malaria vaccines designed for broad use, there is little evidence about scalable delivery strategies in areas with seasonal malaria transmission. We...
The proposed strengthening project for clinical research oversight in ECOWAS region, consists of practical training of regulatory and ethics experts by exposing them to Lassa Fever vaccine...
The integrase inhibitors dolutegravir (DTG) is recommended by the World Health Organization (WHO) for 1st line antiretroviral therapy (ART) in people living with HIV (PLHIV) since 2018...
The spread of Mpox virus (MPXV) in Sub-Saharan Africa, specifically Democratic Republic of Congo (DRC) and Republic of Congo (RoC) presents an urgent public health concern with global...
This proposal is in response to the GH EDCTP3 call for support to EDCTP Africa Office (AO), which is part of the EDCTP Association Secretariat, based in Cape Town and hosted by the South...
The overall goal of this project is to provide scientific evidence for WHO policymaking on the longterm efficacy, safety, acceptability and cost-effectiveness of using R21/Matrix-Malaria...
Cutaneous leishmaniasis (CL) is a neglected tropical disease affecting more than one million people globally each year. In Ethiopia alone more than 40,000 people are thought to be affected...
In spite of high immunization coverage in many countries, pockets of zero-dose (ZD) children still exist as well as communities neglected by current immunisation efforts. The Immunization...